S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage IV Breast Cancer AJCC v8|Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Positive|Prognostic Stage IV Breast Cancer AJCC v8|Elevated CA15-3 or CEA or CA27-29
Interventions: OTHER: Usual care disease monitoring|OTHER: Serum Tumor Marker directed disease monitoring|OTHER: Quality-of-Life Assessment|OTHER: Anxiety Questionnaire Administration
Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)